Week In Review: Allgenesis Posts Positive Data From US Trial Of Bi-Specific For Diabetic Macular Edema

Taiwan’s Allgenesis Biotherapeutics reported positive early data from a US Phase IIa trial of a bi-specific Fc-fusion protein designed to block VEGFs and integrins for Diabetic Macular Edema.